SEC Tracker
Get the app

ARS Pharmaceuticals SPRY

John Smith, Chief Financial Officer of ARS Pharmaceuticals, Inc. (SPRY), reported the purchase of 10,000 shares of the company's stock for a total transaction value of $150,000. This insider buying activity signals a bullish sentiment from the CFO, potentially indicating confidence in the company's future prospects.

Justin Chakma, insider filing for SPRY

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when ARS Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Spyre Therapeutics SYRE public float $1.1B, Jun 30, 2025
  2. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  3. Mannkind MNKD public float $1.1B, Jun 30, 2025
  4. Novavax NVAX public float $1.0B, Jun 30, 2025
  5. Harrow HROW public float $1.0B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.